Botulinum toxin preparations: areas for improvement and issues of standardisation

Scientific relevance. Botulinum toxin preparations are a good example of using a deadly toxin as a unique therapeutic agent. However, there are many unresolved issues related to biotechnology, biological activity, interchangeability, and standardisation of botulinum toxin preparations.

Aim. To review current opportunities for improving therapeutic botulinum toxin preparations.

Discussion. This review covers botulinum toxin type A preparations and unresolved issues related to them. In the absence of international non-proprietary names recommended by the World Health Organisation or by the Board of the Eurasian Economic Commission, domestic and imported botulinum toxin type A preparations approved in Russia have only similarity-based grouping names. In addition, manufacturers name botulinum toxin preparations at their discretion. Therefore, classifying these preparations under a common nomenclature is essential for clear identification, adequate selection, and correct prescription. Several studies have shown significant variability across botulinum toxin type A preparations. Due to the identified differences in qualitative and quantitative characteristics, botulinum toxin type A preparations cannot be considered similar, which raises the issue of their interchangeability and bioequivalence. To resolve this issue, a unified classification and naming system for botulinum toxin preparations should be established and documented in regulatory standards. According to the literature, manufacturers of botulinum toxin preparations use in-house reference standards. Hence, the same activity unit resulting from toxicity and efficacy studies may express a different protein load for each botulinum toxin preparation. Keeping that in mind, the authors discuss the development of a single international potency standard for existing and pipeline botulinum toxin type A preparations.

Conclusions. The article describes novel pharmaceutical compositions containing botulinum toxin, including those in late development. Summarised data from clinical studies on the safety, efficacy, and cost-effectiveness of botulinum toxin type A preparations can guide prescribing decisions.

1. Camargo CHF, Teive HAG. Use of botulinum toxin for movement disorders. Drugs Context. 2019;8:212586. https://doi.org/10.7573/dic.212586

2. Rader RA. Nomenclature of new biosimilars will be highly controversial. Bioprocess Int. 2011;9:26–33.

3. Boone B. Botulinum toxin in aesthetic medicine. In: Katsambas AD, Lotti TM, Dessinioti C, d’Erme AM, eds. European Handbook of Dermatological Treatments. Berlin Heidelberg: Springer; 2015. P. 1089–06. https://doi.org/10.1007/978-3-662-45139-7

4. Choudhury S, Baker MR, Chatterjee S, Kumar H. Botulinum toxin: an update on pharmacology and newer products in development. Toxins (Basel). 2021;13(1):58. https://doi.org/10.3390/toxins13010058

5. Artemenko AR, Kurenkov AL, Belomestova KV. On the absence of interchangeability of botulinum toxin type A drugs. Medical Council. 2015;(5):112–23. (In Russ.). https://doi.org/10.21518/2079-701X-2015-5-112-123

6. Timerbaeva SL. Ineffectiveness of botulinum therapy: an old problem, new solutions. Nervnye bolezni. 2015;(4):28–32 (In Russ.). EDN: VMDAJT.

7. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol. 2000;43(2 Pt 1):249–59. https://doi.org/10.1067/mjd.2000.105567

8. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol. 2006;13(Suppl. 1):2–10. https://doi.org/10.1111/j.1468-1331.2006.01438.x

9. Samizadeh S, de Boulle K. Botulinum neurotoxin formulations: overcoming the confusion. Clin Cosmet Investig Dermatol. 2018;11:273–87. https://doi.org/10.2147/ccid.s156851

10. Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm (Vienna). 2008;115(4):559–65. https://doi.org/10.1007/s00702-007-0728-2

11. Scott AB, Magoon EH, McNeer KW, Stager DR. Botulinum treatment of strabismus in children. Trans Am Ophthalmol Soc. 1989;87:174–80.

12. Brin MF., James C., Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics. 2014;8:227–41. https://doi.org/10.2147/btt.s65603

13. Jabbari B. Basics of structure and mechanisms of function of botulinum toxin — how does it work? In: Jabbari B. Botulinum toxin treatment: What everyone should know. Berlin/Heidelberg: Springer; 2018. P. 11–7. https://link.springer.com/content/pdf/10.1007/978-3-319-99945-6_2.pdf?pdf=inline%20link

14. Scaglione F. Conversion ratio between Botox®, Dysport®, and Xeomin® in clinical practice. Toxins (Basel). 2016;8(3):65. https://doi.org/10.3390/toxins8030065

15. Brodsky MA, Swope DM, Grimes D. Diffusion of botulinum toxins. Tremor Other Hyperkinetic Mov (N Y). 2012;2:p.tre-02-85-417-1. https://doi.org/10.5334/tohm.120

16. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M; CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23(10):1353–60. https://doi.org/10.1002/mds.22157

17. Dressler D. Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins. Eur J Neurol. 2012;19(3):385–9. https://doi.org/10.1111/j.1468-1331.2011.03559.x

18. Park JY, Sunga O, Wanitphakdeedecha R, Frevert J. Neurotoxin impurities: a review of threats to efficacy. Plast Reconstr Surg Glob Open. 2020;8(1):e2627. https://doi.org/10.1097%2FGOX.0000000000002627

19. Hanna E., Pon K. Updates on botulinum neurotoxins in dermatology. Am J Clin Dermatol. 2020;21(2):157–62. https://doi.org/10.1007/s40257-019-00482-2

20. Manturova NE, Chaikovskaya EA, Timerbayeva SL. Botulinum toxin therapy: what do we have and what do we see on the horizon? Plastic Surgery and Aesthetic Medicine. 2020;(2):70–80 (In Russ.). https://doi.org/10.17116/plast.hirurgia202002170

21. Ascher B, Rzany B, Kestemont P, Hilton S, Heckmann M, Bodokh I, et al. Liquid formulation of abobotulinumtoxinA: a 6-month, phase 3, double-blind, randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthet Surg J. 2020;40(1):93–104. https://doi.org/10.1093/asj/sjz003

22. Ascher B, Kestemont P, Boineau D, Bodokh I, Stein A, Heckmann M, et al. Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator–controlled trial. Aesthet Surg J. 2018;38(2):183–91. https://doi.org/10.1093/asj/sjw272

23. Poewe W, Burbaud P, Castelnovo G, Jost WH, Ceballos-Baumann AO, Banach M, et al. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: a randomized-controlled trial. Mov Disord. 2016;31(11):1649–57. https://doi.org/10.1002/mds.26760

24. Monheit GD, Nestor MS, Cohen J, Mitchel PG, Gold MH, Tichy EH, Swinyer L. Evaluation of QM1114, a novel ready-to-use liquid botulinum toxin, in aesthetic treatment of glabellar lines. In: 24th World Congress of Dermatology “A new ERA for global dermatology”. Milan; 2019. https://www.wcd2019milan-dl.org/abstract-book/documents/late-breaking-abstracts/03-aesthetic-cosmetic-dermatology/evaluation-of-qm1114-a-novel-490.pdf

25. Kutschenko A, Weisemann J, Kollewe K, Fiedler T, Alvermann S, Boselt S, et al. Botulinum neurotoxin serotype D — a potential treatment alternative for BoNT/A and B non-responding patients. Clin Neurophysiol. 2019;130(6):1066–73. https://doi.org/10.1016/j.clinph.2019.02.007

26. Rystedt A, Karlqvist M, Bertilsson M, Naver H, Swartling C. Effect of botulinum toxin concentration on reduction in sweating: a randomized, double-blind study. Acta Derm Venereol. 2013;93(6):674–8. https://doi.org/10.2340/00015555-1606

27. Bentivoglio AR, del Grande A, Petracca M, Ialongo T, Ricciardi L. Clinical differences between botulinum neurotoxin type A and B. Toxicon. 2015;107(Pt A):77–84. https://doi.org/10.1016/j.toxicon.2015.08.001